{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hofmeyr GJ"],"funding":["World Health Organization","Swedish International Development Cooperation Agency","Medical Research Council of South Africa","United States Agency for International Development","Bill and Melinda Gates Foundation"],"pagination":["17"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5771152"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["1"],"pubmed_abstract":["<b>Background:</b><i>In vitro</i>, animal, biological and observational clinical studies suggest that some hormonal methods, particularly depot medroxyprogesterone acetate - DMPA, may increase women's risk of HIV acquisition. DMPA is the most common contraceptive used in many countries worst affected by the HIV epidemic. To provide robust evidence for contraceptive decision-making among women, clinicians and planners, we are conducting the Evidence for Contraceptive Options and HIV Outcomes (ECHO) study in four countries with high HIV incidence and DMPA use: Kenya, South Africa, Swaziland, and Zambia (Clinical Trials.gov identifier NCT02550067). <b>Study design:</b> We randomized HIV negative, sexually active women 16-35 years old requesting effective contraception and agreeing to particip"],"journal":["Gates open research"],"pubmed_title":["Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study)."],"pmcid":["PMC5771152"],"funding_grant_id":["001","OPP1032115","AID-OAA-A-15-00045"],"pubmed_authors":["ECHO Trial Team","Baeten JM","Rees H","Gichangi P","Steyn P","Mugo N","Taylor D","Chipato T","Hofmeyr GJ","Donnell D","Nanda K","Morrison CS"],"additional_accession":[]},"is_claimable":false,"name":"Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study).","description":"<b>Background:</b><i>In vitro</i>, animal, biological and observational clinical studies suggest that some hormonal methods, particularly depot medroxyprogesterone acetate - DMPA, may increase women's risk of HIV acquisition. DMPA is the most common contraceptive used in many countries worst affected by the HIV epidemic. To provide robust evidence for contraceptive decision-making among women, clinicians and planners, we are conducting the Evidence for Contraceptive Options and HIV Outcomes (ECHO) study in four countries with high HIV incidence and DMPA use: Kenya, South Africa, Swaziland, and Zambia (Clinical Trials.gov identifier NCT02550067). <b>Study design:</b> We randomized HIV negative, sexually active women 16-35 years old requesting effective contraception and agreeing to particip","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017","modification":"2026-04-07T16:45:08.128Z","creation":"2019-03-26T22:58:53Z"},"accession":"S-EPMC5771152","cross_references":{"pubmed":["29355224"],"doi":["10.12688/gatesopenres.12775.2"]}}